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ABSTRACT 
 
Fungal infections are more common today than ever before. Increasing rates of invasive 
procedures, bone marrow transplants, and the use of immunosuppressive agents and broad 
spectrum antibiotics have resulted in an increasing susceptibility to nosocomial infections, 
mainly fungal infections. Higher morbidity and mortality rates associated with drug resistance 
have led to a greater need for the development of new, more effective compounds that support 
the action of the marketed antifungal agents.  In this project, the anti-Candida activity of the 
terpenoid component of the plant essential oil—Geraniol was investigated. This was achieved 
using minimum inhibitory concentration assays (MIC).  Furthermore, the synergistic activity of 
Geraniol combined with the known azole Fluconazole was also evaluated for increased efficacy 
against Candida albicans in vivo. The susceptibility of the fungus to the combination was 
measured by the amount of cell growth seen after exposure to the mixture. The data indicate a 
synergistic activity of the Geraniol-Fluconazole mixture against drug-resistant C. albicans. 
Various mutant strains of C. albicans, expressing different levels of resistance were also tested in 
the study.  Checkerboard MIC assays, with serial dilutions of the azole and Geraniol were used 
to assess synergy. 
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INTRODUCTION 
 
 
Fungal infections caused by Candida albicans are one of the most prevalent nosacomial 
infections. These infections cause significant cases of fatality, and contribute to millions of 
dollars annually in medical bills associated with prolonged patient stay at hospitals. Known 
antifungal agents include mainly azoles and polyenes. Azoles have been used to treat C. albicans 
infections such as vaginitis, which is the most common gynecological disorder affecting women, 
as well as candidiasis, the most highly prevalent infection in patients suffering from HIV.  
Candida infections are usually manifested in individuals with compromised immune systems, 
such as those suffering from cancer or HIV.  In more serious conditions, Amphotericin B—one 
of the oldest antifungal agents, a polyene—is often used. As with most infectious agents, C. 
albicans may develop resistance to antifungal medications, resulting in recurring infections. 
Major causes of this resistance include untimely and improper drug administration, high 
antibiotic intake, or a compromised immune system that allows the fungus to grow and flourish. 
This problem is the basis of this project, which aims to determine a means of overcoming C. 
albicans resistance to antifungals, specifically the resistance to the azole Fluconazole. 
In order to address  the  question,  “How  can  Candida albicans resistance to azole 
antifungals  be  overcome?”  it  was  critical  to  understand  some  of  the  common  azole resistance 
mechanisms employed by the fungus.  Some molecular mechanisms of azole resistance include 
the over-expression of the efflux pump and/or over-expression of the ERG11 target enzyme. 
These resistance mechanisms compromise the effectiveness of azole antifungal drugs.  Fungal 
acquisition of resistance to drugs has resulted in greater numbers of difficult to treat fungal 
infections thus expanding the need to overcome this problem.  Overcoming fungal resistance to 
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antifungal drugs might involve using enhancing compounds or alternative drugs to treat patients. 
Previous studies have shown the anti-Candidal effects of essential oils produced by plants 
(Chami et al., 2005). The active compounds in essential oils are monoterpenoids (terpenes), 
which are believed to have protective functions in plants. Terpenes act by permeabilizing cellular 
membranes, and were therefore selected as the class of enhancing compound for this study, 
exploring possible synergistic effect resulting from their combination with antifungal drugs. We 
hypothesized that terpenes would both inhibit Candida growth themselves and synergistically 
overcome Fluconazole resistance by C.albicans when combined with the azole. 
This study investigated the antifungal effects of the terpenes: Carvacrol and Geraniol 
when combined with the antifungal agents: Fluconazole and Amphotericin B, against several 
resistant clinical isolates of C. albicans. Possible synergies between the terpenes and antifungal 
drugs were evaluated and used to determine whether such drug combinations could realistically 
alleviate the Candida resistance to antifungal agents in clinical use.  
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BACKGROUND 
 
Candida albicans     
 
Fungi are a highly successful and diverse group of eukaryotic organisms consisting of 
approximately 300,000 different species. C. albicans is the most common pathogenic fungus 
affecting humans ( Hull et al., 2000). Unlike other fungal pathogens, this dimorphic fungus exists 
in two different morphological shapes simultaneously. One form is a yeast-like state that is a 
non-invasive, sugar-fermenting organism. The other is a fungal form that produces very long 
root-like structures called rhizoids ( Shena et al., 2008). This latter rhizoid form is believed to be 
invasive—a causal agent of opportunistic oral and genital infections in humans. To infect its host 
tissue, the usual unicellular yeast-like form of C. albicans responds to its surrounding 
environmental signals and changes into the invasive, multicellular filamentous form. This 
phenomenon defines dimorphism.  C. albicans does not reproduce sexually. The exterior of the 
C.albicans cell is made up of many types of polysaccharides such as, glucans, chitin, and 
mannans—mainly giving structure to the cell wall. The cellular membrane structure of C. 
albicans is considered a dynamic organelle, with ergosterol being the main membrane sterol. 
Figures 1 and 2 below show C. albicans fungi under a microscope in its normal and pathogenic 
form, respectively. 
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C. albicans is capable of proliferating within the human body where it can lead to 
infections such as oral thrush, vaginitis, and athletes feet.  This pathogen enters its human or 
animal host by penetration through a colonized surface. Candida contains virulence factors that 
facilitate its potential to infect an organism. These virulence factors include surface molecules 
that facilitate Candida adherence to other structures. It also contains acid proteases and 
phospholipids involved in penetration and damage of cell envelopes. Furthermore, Candida’s  
ability to convert into the hyphal form is crucial for pathogenic activity (Shena et al., 2008). 
Once it is within its host organism, Candida proliferates in dark and moist environments, and is 
most often present in the mouth, feet, vagina, and gastrointestinal tract. Candida can also travel 
through the bloodstream, and can therefore be found anywhere in the body from the brain to the 
lungs, muscles, or joints. 
Figure 2: Microscopic image of the cells of 
pathogenic C. albicans with hyphae 
(Lewis, 2011) 
                    Figure 1:  Microscopic image of the cells of the normal yeast- like fungus C. albicans (Volk, 1999) 
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Like most other microorganisms that live in the intestine, C. albicans lives in symbiosis 
with the other microorganisms present within the host, mostly intestinal bacteria in humans. The 
fungus lives in about 80% of the human population without causing harmful effects.  Because 
Candida has the tendency to proliferate at a high rate, this symbiosis is necessary to maintain 
proper  function  of  its  host’s  physiological systems—overgrowth of the fungi can cause health 
complications. The Candida to  bacteria  ratio  can  be  disrupted  if  the  number  of  “good  bacteria”  in  
the host is lowered, through antibiotic administration for instance. Another cause for the 
disruption of this ratio is an imbalance of sugars relative to vitamins and other key nutrients 
required to sustain bodily functions. Candida feeds on various sugars; therefore an abnormally 
high amount of sugars in the blood stream can fuel Candida growth.  Both an irregularly low 
bacterial population and unusually high blood sugar level will lead to a sprouting of the key 
diseases associated with an increase in Candida population. Furthermore, this uncontrolled 
Candida proliferation is facilitated by defects in its host immune system, such as mucocutaneous 
wounds and granulocytopenia. The molecular biology of C. albicans is chiefly based on the 
molecular knowledge of the yeast Saccharomyces cerevisiae. This is due to the fact that they are 
similar, and because C. albicans genes can be expressed in Saccharomyces (Molero et al., 1998). 
 
 
Diseases Caused by C. albicans     
 
Candidiasis or thrush is a fungal infection (mycosis) of any of the Candida species (all 
yeasts), of which Candida albicans is the most common. As Cynthia Perkins (2007) writes, “On  
a daily basis, virtually all physicians are confronted with a positive Candida isolate obtained 
from  one  or  more  various  anatomical  sites”.   According to an epidemiological review by Dr.  
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Hidalgo (2011), there is a 30-55% Candida colonization of the oral airway of healthy young 
adults, and a 40-65% Candida colonization of normal fecal florae.  Dr. Hidalgo further reports 
that Candida species are the fourth most commonly isolated pathogens from blood cultures. This 
demonstrates the large Candida presence in the microflorae of humans, and the danger for 
Candida infection posed to immunocompromised persons. 
Vulvovaginal candidiasis (VVC) is the second most common cause of vaginitis in 
women, and is the most common condition affecting women seeking gynecologic primary care. 
Nearly 75% of all adult women have had at least one "yeast infection" in their lifetime (CDC, 
2012).  VVC is characterized by vaginal discharge, burning, and vulvar irritation, and the 
Candida genus is the specific cause for this infection (PubMed Health, 2010).  According to an 
article on VVC by Dr. Samra-Latif (2012), three out of four women experience at least one 
attack of VVC in their lifetime, backing up the 75% CDC estimate mentioned above. 
Approximately half of these women will have more than one episode, and a few will have 
frequent relapses. The United States estimates indicate that about 50% of college-aged women 
will experience a VVC episode. 
Candidiasis infections range from the superficial types (oral thrush, athlete’s  foot,  and  
vaginitis, Figures 3 and 4) to the systemic types which are potentially life-threatening 
(candidemia). A superficial infection does not penetrate the bloodstream, while systemic 
infections do.  Systemic fungal infections may be caused either by an opportunistic organism that 
attacks a person with a weakened immune system, or by an invasive organism common in a 
specific geographic area. Candidiasis is highly prevalent in immunocompromised persons, such 
as cancer, transplant, and AIDS patients, as well as non-trauma emergency surgery patients.  
About 90% of HIV patients not treated with highly active antiretroviral therapy develop 
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oropharyngeal candidiasis (of the oral pathway), and 10% develop esophageal candidiasis 
(Perkins, 2007).  Although mucocutaneous candidiasis rarely causes death in patients with strong 
immune systems, it can lead to poor oral intake, malnutrition, and early death in patients with 
advanced immunodeficiency due to HIV infection. 
   
                                                                                              
 
 
 
 
However, disseminated candidiasis is associated with much higher mortality rates 
ranging from 30-40%. According to Dr. Hidalgo (2011),  “Systemic  candidiasis  causes  more  case  
fatalities than any other systemic mycosis, [and] investigators reported the enormous economic 
impact  of  systemic  candidiasis  in  hospitalized  patients  [over  a  decade  ago]”.  Systemic 
candidiasis can easily prolong patient hospital stay by a month, which causes greater healthcare 
costs. 
 
Figure 3: Oral Thrush Caused by C.albicans.  
A close-up of the white tongue caused by 
oral thrush in affected patient (Marazzi, 
n.d.). 
 Figure 4: Clinical manifestations of candidiasis in 
the toes (Volk, 1999).                                                                                                                         
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Antifungal Drugs 
 
Fungi are emerging as a major nosocomial agent of infectious disease, and the rate of 
fungal infections, particularly those caused by Candida species has risen significantly in the past 
few decades. Between 1980 and 1990, there were 30,477 reported fungal infections in the U.S. 
Data from the National Nosocomial Infections Survellience System reported an increase in the 
number of infections/1000 discharge from 2.0 to 3.8 (Beck-Sagué et al., 1993).   
Antifungal drugs work by exploiting the differences between mammalian and fungal 
cells. Both fungi and animals are eukaryotes, thus there is difficulty in designing drugs that 
specifically target fungi without affecting human cells. In the United States, there are about 10 
antifungal drugs approved by the FDA to treat systemic fungal infections. Generally, these drugs 
fall under four main categories of antifungal agents: polyenes, azoles, echinocandins, and 
pyrimidines (Dismukes, 2000).  Other drugs are available for treating superficial infections. 
Compared to superficial infections, systemic fungal infections can be life-threatening. 
Amphotericin B is a major drug in the market against fungal infections. This polyene exerts its 
pharmacological effects by forming a barrel-stave assembly in fungal membranes (Murata et.al., 
2009). Amphotericin B specifically interacts with membrane sterols upon forming an ion channel 
assembly. This accounts for its selectivity against fungi, and in particular the yeast C. albicans, 
which has a sterol membrane containing ergosterol (Baginski et al., 1997). Amphotericin B is a 
polyene macrolide antifungal agent that has been the major drug choice for the treatment of 
systemic fungal infections for over 40 years. Even though there are newer antifungal agents such 
as the azoles, Amphotericin B remains a popular antifungal choice (Gallis et.al, 1990).  Although 
Amphotericin B is highly effective against fungal infections, its dose-dependent toxicity 
characterized by fever, chills, vomiting and nausea limits its usefulness (Lemke et al., 2005). 
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In  order  to  overcome  Amphotericin  B’s  detrimental  nephrotoxic  effects,  new  
pharmaceutical lipid formulations have been developed.  These lipid formulations are 
Amphotericin B lipid complex, Amphotericin B cholesteryl sulfate, and liposomal Amphotericin 
B. These formulations have the advantage over conventional Amphotericin B as they better 
deliver the drug to the tissues, and have milder or less acute side effects (Dismukes, 2000). 
However, they are expensive. Amphotericin B is often combined with other antifungal drugs to 
tackle fungal infections. 
The next set of antifungal agents: azoles have provided more options for the treatment of 
fungal infections. The availability of azole antifungal agents in recent decades has created a 
significant therapeutic advance for treating fungal infections. Azoles are made up of nitrogen 
containing five-membered organic rings. They are divided into two classes: the imidazoles—
clotrimazole, miconazole, ketoconazole—and the triazoles—Itraconazole and fluconazole— 
(Baron, 1996). There is a wide variety of these agents in the form of ointments, creams, and 
powders to treat cutaneous dermatophyte and some yeast infections (Bodey, 1992). 
The principle mechanism of action of azole antifungal agents is to selectively inhibit Lanosterol 
14α-demethylase, a fungal cytochrome P-450 enzyme encoded by the ERG11 gene. These 
enzymes are present in most living cells including fungi and yeasts, and they catalyze the 
conversion of lanosterol to ergosterol, which is a major component of the fungal cell membrane. 
Thus, azoles inhibit the production of ergosterol. Furthermore, they might also affect fatty acids 
of the cell membrane, interfering with transport across the membrane, inhibiting the catalase 
systems and decreasing fungal adherence (Bodey, 1992). A schematic visualization of the azole 
action is shown in Figure 5. 
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Figure 5: Mechanism of Azole Antifungal Activity. 
 
As the figure above shows, the Azoles are effective because they selectively inhibit 
fungal enzymes (lanosterol  14α-demethylase) over mammalian ones, inhibiting ergosterol 
synthesis. Azoles can tackle a broad spectrum of fungal pathogens including Candida species, 
and their effectiveness is exceeded only by Amphotericin B. Compared to Amphotericin B, their 
ease of administration as well as their lower toxicity levels makes the oral azoles: ketoconazole, 
itraconazole, and fluconazole, a preferred substitute (Como et al., 1994).  Flucanozole is 
specifically preferred because it is rapidly absorbed, crosses the blood-brain barrier, and is 
minimally metabolized in the liver, with the bulk of the active ingredient excreted in urine 
(Como et al., 1994).  However, side effects of the azoles may include liver toxicity over a long 
period of time, nausea, and vomiting. Miconazole, the first azole in the market was withdrawn 
because of its toxicity and limited activity (Bodey, 1992). 
Ketoconazole can be administered both orally and topically, and is potent against a range 
of infections. Some of these infections are caused by fungi such as H. capsulatum and B. 
dermatitidis, for which ketoconazole is often used in non-immunocompromised patients. 
Ketoconazole is not indicated for treatment of yeast systemic infections. The triazoles, 
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fluconazole and itraconazole, have become the standard for the azoles, and have replaced 
Amphotericin B for managing certain forms of the systemic mycoses. Fluconazole is now 
routinely used to treat candidiasis in non-neutropenic hosts, and is gaining acceptance for use in 
cryptococcosis and selected forms of coccidioidomycosis. Itraconazole has proven to be effective 
for histoplasmosis, blastomycosis, sporotrichosis, coccidioidomycosis, consolidation treatment 
for cryptococcosis, and certain forms of aspergillosis. Fluconazole can be administered either 
orally, or intravenously.  
The fungal cell wall is an attractive target for echinocandins. It inhibits β1,3-glucan 
synthase. Fungi have cell walls, but mammals do not. Furthermore, the enzyme is active outside 
the cell, so the drug does not need to enter the cell. Additional advantages of echinocandins 
include low toxicity and rapid fungicidal activity against most isolates of Candida spp. The first 
licensed echinocandin product was caspofungin acetate (Cancidas; Merck), and others include 
micafungin (Fujisawa). 
Among the pyrimidines, flucytosine is the only one approved for antifungal use. 
However, this water soluble pyrimidine can only work on a small range of species such as 
Candida, Cryptococcus neoformans, and some molds (Dismukes, 2000). Furthermore, it is toxic, 
and develops resistance readily when used. It is therefore used in combination with Amp B for 
treatment of certain fungal infections (Francis et al., 1992). Flucytosine is converted to 5-
fluorouracil (5-FU) by the enzyme cytosine deaminase in certain fungi. This in turn is converted 
to 5-fluoro-2'-deoxyuridylic acid (FdUMP), which inhibits thymidylate synthtase, inhibiting 
DNA synthesis (Waldorf et al., 1983).   A summary of the mechanism by which the different 
classes of antifungal drugs in clinical use exhibit their effect on the C.albicans cells is shown in 
Figure 6. 
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Fungal Drug Resistance 
 
Drug resistance is complex, but may be termed as the persistence of a disease despite 
treatment with the appropriate drug. The last couple of decades have witnessed a transition in 
medicine, especially the use of new types of toxic agents to control and kill unwanted disease 
agents including fungi. Unfortunately, biological evolution and natural selection facilitate the 
emergence of drug resistant pathogenic microorganisms. Antimicrobial agents almost completely 
kill the entire pathogenic population, leaving survivors to evolve resistance (Taylor et al., 1996).  
Opportunistic fungal infections are a threatening problem causing significant morbidity 
and mortality, especially for those with weakened or compromised immune systems such as 
AIDS and cancer patients (Kanafan et al., 2008).  Candida infections have increased 
dramatically since the onset of the AIDS epidemic, and so has Candida resistance. With only a 
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hand full of antifungal drugs on the market, and the increasing occurrence of fungal infections, 
the emergence of drug resistance in fungal pathogens compromising the effectiveness of the 
drugs presents a serious health issue. For this reason, the evaluation of the susceptibility of a 
specific pathogen to a drug is important. Drug resistance by a pathogen is typically measured 
using a minimum inhibitory concentration (MIC) assay (Reyes et al., 2000). MIC assays 
determine the minimum concentration of drug required to show a visual effect on pathogen 
growth.  The effect on growth can also be determined by quantitating the amount of drug that 
provides a specific percentage drop in infection relative to WT, such as 50% (MIC50). 
Microbiological antifungal resistance is either primary (intrinsic) or secondary (acquired). 
Primary resistance can occur naturally among some fungi types without prior exposure to the 
drug.  Secondary resistance is acquired when susceptible fungi strains are exposed to the 
antifungal agent, and this is generally dependent on gene mutations. Fluconazole resistance 
among C. albicans is an example of a secondary resistance (Pfaller, 2012). 
Clinical resistance occurs when the pathogen is inhibited by an antimicrobial drug 
concentration that is greater than could be safely achieved with normal dosing. These failures 
could be due to a combination of factors from the pathogen, the host, or the drug itself (Kanafan 
et al., 2008). Generally, resistance is said to be present when the infection is persistent, despite 
the use of the usual concentrations of the agent with normal dosage schedules, and/or when the 
pathogen  shows  MIC’s  that  fall  within  the  range  of  resistance  strains. 
As explained above, antifungal agents combat the pathogens through different 
mechanisms. The azole antifungals inhibit the enzyme that makes ergosterol, which is the major 
component of the fungal cell wall (Bodey, 1992). As a result, ergosterol content in the cell 
membrane is depleted, leading to improper functioning of the membrane, which leads to fungal 
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cell death. The mechanism of resistance of fungi to azoles has been well characterized, however 
resistance for the other classes of antifungal drugs is still being investigated. 
The main known mechanisms of resistance to azoles in Candida species are: 1) active 
efflux pump development, 2) mutation of the ERG11 gene, 3) overexpression of the target 
enzyme, and 4) the development of bypass pathways. Active efflux pump development results in 
decreased drug concentrations at the site of action. Efflux pumps are encoded in the Candida 
species by two transporter families: the CDR genes of the ATP binding cassette super-family, 
and the MDR genes of the major facilitators’  class.  Up-regulation of efflux pumps (MDR1, 
CDR1, CDR2) encoded by either gene results in Candida resistance to azoles. CDR gene 
overexpression confers resistance to nearly all azoles; however MDR encoded efflux pumps 
usually select for fluconazole specifically (Kanafan et al., 2008).  
The second form of antifungal resistance encountered is one facilitated through mutations 
in the ERG11 gene that encodes the target enzyme. This target enzyme, lanosterol C14a-
demethylase, prevents or reduces binding of azoles to the enzymatic site (Löffler et al., 1997). 
The third resistance mechanism is overexpression of the altered Lanosterol  14  α-
demethylase target enzyme. This may lead to targets not binding well with the azole drugs and 
inhibiting ergosterol synthesis. However, minimal up-regulation of altered target enzymes has 
been observed to date, and so this mechanism contributes little to the resistance observed.   
The final known mechanism of azole resistance in Candida species involves the 
development of bypass pathways. This negates the membrane-disruptive effects of azole drugs. 
This mechanism has been linked with mutation of the ERG3 gene in certain resistant strains of 
Candida (Kelly et al., 1997).  
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Polyenes like amphotericin B and its lipid formulations act by forming a barrel-stave 
assembly in fungal membranes in close association with ergosterol. This leads to porin channel 
formation, and the loss of transmembrane potential and impaired cell functioning (Murata et al., 
2009). Resistance breakpoints for polyenes have not yet been determined.  An MIC of ≥1.0 
µg/mL is widely used to indicate resistance to Amphotericin B. Mutations in the ERG3 gene 
involved in erogosterol synthesis lead to a buildup of other sterols in the fungal membrane. 
Polyene resistant strains of Candida have relatively low ergosterol content, compared to 
sensitive strains (Dick et al., 1980). 
Resistance of clinical isolates of C. albicans to the echinocandin drug caspofungin is 
slowly developing. It is related to mutations in short conserved regions in the FKS1gene. The 
most prominent changes occur at the serine 645 position in Fks1p with substitutions of proline, 
tyrosine, and phenylalanine. An allele-specific real-time PCR molecular-beacon assay has been 
developed for rapid identification of drug resistance by targeting FKS1mutations. Mutations 
altering serine 645 were reliably identified in both heterozygous and homozygous states. 
Pyrimidines such as flucytosine inhibit cellular DNA and RNA synthesis by inhibiting 
the enzyme thymidylate synthtase (Waldorf et al., 1983). Some yeast strains are intrinsically 
resistant to this drug because of decreased cellular uptake of the drug due to a mutation in 
cytosine permease.  However, acquired resistance can also occur through defects in flucytosine 
metabolism caused by mutations in cytosine deaminase or uracil phosphoribosyl transferase. 
However, resistance to flucytosine is readily developed by fungi, prompting clinicians to use 
flucytosine only in combination with other antifungal agents, mainly Amphotericin B (Francis et 
al., 1992).  A summary of the various resistance mechanisms applied by the different drug 
classes is shown in Figure 7.  
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Figure 7: Drug resistance mechanisms in C. albicans. (A) C. albicans develops resistance to the azoles through several 
mechanisms including the upregulation and or alteration of the target Erg11; the increased expression of the efflux pump—
Cdr1, Cdr2, or Mdr1 (fluconazole specific); or through cellular stress responses. (B) C. albicans resistance to the polyenes is 
infrequent, but developed by loss-of-function mutations in ERG3, blocking the production of ergosterol and the formation of 
the drug-lipid complex, thereby preventing osmotic cellular lysis. Alteration in drug transporters and cellular stress responses 
do not contribute much to polyenes resistance. (C) Resistance to the echinocandins, mainly through mutations in two distinct 
hot-spot regions in FKS1, encoding the catalytic subunit of (1,3)-β-d-glucan synthase, has been observed. The induction of 
cellular stress responses is important for echinocandin resistance. Bright images show key mechanisms for a given class of 
drug (Cowen, 2008) 
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Terpenes 
 
Antifungals make up a small but important group of drugs in the market. This is largely 
due to the growing incidence of failure in the treatment of fatal fungal infections, mostly due to 
resistance and or opportunistic infections in immunocompromised patients. This has resulted in 
the need for newer, more effective fungal agents or enhancers for the treatment of affected 
patients.  The history of drug discovery shows that many of the most successful therapeutics 
come from natural sources like plants (Bevan et al., 1995). Plant essential oil extracts, in addition 
to defending plants against predators, pathogens, and competitors, also have antiseptic qualities 
that have been recognized since antiquity. Attempts to characterize these properties in the 
laboratory date back to the early 1900s (Hoffmann and Evans, 1911). These volatile oils are 
generally obtained from non-woody plant material by distillation methods that typically include 
steam or hydro distillation. Plant essential oils are principally made up of terpenoids and a 
variety of low molecular weight hydrocarbons. Although they usually occur as complex 
mixtures, their activity can primarily be accounted for in terms of their major monoterpenoid 
components (Cox et al., 2001). Terpenes are primary chemicals responsible for the medicinal, 
culinary and fragrant uses of aromatic and medicinal plants. 
The antifungal effect of plant essential oils and their promise to enhance the activity of 
antifungal drugs already in the market has been established. Several studies including the one 
performed by Chami et al. (2005) titled  “Study of anti-Candida activity of carvacrol and eugenol 
in vitro and in vivo”  have  proven  the  antifungal  activity  of  terpenes.  In  this  particular  study,  the 
anti-Candida activity of eugenol and carvacrol was tested against C.albicans in 
immunosuppressed rats. The fungicidal effect of these terpenes significantly reduced the fungi 
growth.  
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Research into the antimicrobial actions of terpenes suggests that they destroy and damage 
the cellular membrane. They move into the cell membrane by diffusion, increasing the plasma 
membrane permeability (Andrews et al., 1980). Another study performed by Salvador Uribe et 
al. (1985) titled  “Effects  of  P-Pinene on Yeast Membrane  Functions”  suggests  inhibition  of  
respiration with glucose or ethanol as the substrate. The inhibition depended on the ratio of the 
terpene to the amount of yeast cells; for a fixed concentration of terpene, inhibition decreased as 
the amount of yeast cells increased. The terpene also inhibited the pumping of protons and K+ 
transport. The studies on isolated mitochondria showed a series of effects, starting with the loss 
of respiratory control and de-energization of the organelles. This was followed by an inhibition 
of respiration at higher concentrations of the terpene. The effect on respiration could be localized 
to the cytochrome b region of the electron transport chain. No effect could be detected on the 
activity of ATPase (Uribe et al., 1985). 
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PROJECT PURPOSE 
 
The goal of this investigation was to test for potential synergy between a known 
antifungal drug and essential plant oils: terpenes. To do this, the Minimal Inhibitory 
Concentration (MIC) of antifungal agents and terpenes against a series of sensitive and resistant 
Candida strains was determined.  The synergistic effect of Geraniol on fluconazole activity was 
quantified for five drug-resistant Candida isolates. The identification and quantification of the 
extent of synergy, as well as the understanding of the means by which resistance was overcome 
will facilitate the development of novel therapies against resistant Candida strains. On a larger 
scale, such therapies offer the potential of eliminating the problem of recurrent fungal infections. 
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METHODS AND MATERIALS 
 
 
Candida Strains 
 
Seven Candida strains were used in this study. Strains 1, 3, 14, 17, 4568, were a gift from 
Professor Theodore White, and strains 10261, and 51611 were from ATCC. These strains are 
mutated to show different levels of resistance to antifungals.   The yeast strains were grown in 
Yeast Peptone Dextrose (YPD) Broth and were stored at -70°C in 20% glycerol until tested.  For 
each experiment, the yeasts were grown from frozen culture in YPD broth for 16 h at 37°C for 
inoculum preparation, and diluted  in saline to a cell density of 105/ml. 
 
 
Antifungal Drugs 
 
The antifungal activities of the essential oils Geranoil and Carvacrol were evaluated. 
Geranoil and Carvacrol were purchased from Penta Chemicals. Known antifungals used in the 
study were Fluconazole (from TCI America), and Amphotericin B (from Sigma).  
 
Essential Oils and Chemicals 
 
Powders of fluconazole and amphotericin B were dissolved in 100 % dimethyl 
sulphoxide (DMSO) from Sigma at 1000 mg/ml and 100 mg/ml, respectively, and stored at   
-20°C.  Individual aliquots of each solution were used. Based on the concentration needed, the 
appropriate aliquot was dissolved in the calculated volume of YPD. The calculations took into 
account the percent of DMSO present in the final solution before application to the yeast cells. 
The maximum amount of DMSO allowed was 5% DMSO—this ensured that the solvent did not 
contribute to the killing/inhibition of growth seen.  The essential oil components Geranoil and 
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Carvacrol were kept at room temperature throughout the experimental period, and appropriate 
volumes were diluted in YPD before MIC and Checkerboard MICs were performed.  
 
Minimal Inhibitory Concentration (MIC) Assay 
MIC testing was completed according to the National Committee for Clinical Laboratory 
Standards (NCCLS) approved standard M27-A for the reference method for broth dilution 
antifungal susceptibility testing of yeast. To test the MIC of antifungal drug, different 
concentrations of the dissolved drug in DMSO were further diluted in YPD to prepare the 
required starting concentration. The assay was performed in 96-well flat bottom microtiter plates. 
180 ul YPD growth media was pipetted into all the 96-wells aseptically, followed by 20 ul of the 
antifungal agent (azole, polyenes or essential oil) into the first well of each column. Using a 
multichannel pipette, the media and drug were mixed in the first row thoroughly by pipetting up 
and down multiple times. Then 100 ul of the mixture was transferred to the next row of wells, 
and repeated until row H, the last 100 ul of mixture was discarded so that all wells contained 100 
ul (see Figure 8). Candida dilutions resulting in ~105 cells/ml population in YPD for each of the 
strains tested were made, and a 100 ul volume of the assigned candida strain was added 
corresponding to each well/column. Absorbance readings were taken at time 0 using a microplate 
spectrophotometer (Tecan) at 550 nm, and plates were incubated for about 24 hours at ~37°C. 
Absorbance readings were taken at the end of this time to determine turbidity of the well 
contents. Also, the plates were scored microscopically to compare with the spectrophotometric 
readings. 
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Checkerboard Microtiter Assay 
 
To characterize and quantify the antifungal activity of Fluconazole, Geraniol, and the 
drug combinations over a range of concentrations, these compounds were tested in a 
Checkerboard microtiter plate format (96-well polystyrene plates) (Figure 9). The experiments 
were performed according to NCCLS approved standard M27-A. The MICs obtained from the 
NCCLS standard method performed above were used as basis for the concentration of drugs to 
start with. The stock solution of Fluconazole (in 100% DMSO) and Geraniol were used to 
prepare the desirable concentration of each by further dilution in YPD medium (generally 20X> 
MIC calculated). The  dilution  was  such  that  the  amount  of  DMSO  was  ≤  5%  by  volume,  as  
DMSO might have a toxic activity against C. albicans. Necessary Candida dilutions resulting in 
~105 cells/ml population in YPD for each of the strains tested was performed. To perform the 
assay, 100 ul of YPD was added to each well, followed by 100 ul 20X MIC of fluconazole to 
Figure 8: Setup of the MIC Plate.  Strains are allocated to each column (1-10) of 
the plate. Fluconazole or Geraniol is added to well A of each column. This initial drug 
concentration is halved with each subsequent row until H. Column 11 is a positive 
control containing each C. albicans strain in separate wells with no drug added. 
Column 12 is a negative control and does not contain C. albicans or drug in any of its 
wells.  
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Rows A- H of Column 1. Next, 100 ul of the YPD-fluconazole was transferred from Column 1 to 
Column 2, from Column 2 to Column 3, and so forth.  Care was taken for 100 ul to be dispensed 
from Column 11, and for this volume to not be added to Column 12. Geraniol dilutions were 
performed assuming the weight of the oil was equal to its volume. Following the addition of 
Fluconazole, 100 ul of Geraniol at 20X MIC was added to Row A of Columns 1-12. The 
contents of these wells were vogorously mixed by pipetting up and down, after which 100 ul of 
the contents were transferred from Row A to B for Columns 1-12, Row B to C and so on. The 
contents of Row G were not transferred into Row H, rather they were disposed of. 
The Checkerboard MIC endpoint was defined as the lowest Fluconazole and Geraniol 
concentrations at which a prominent decrease in turbidity was observed. This corresponded to a 
growth  inhibition  of  ≥90% when the viable counts were compared to those of the growth control. 
The interaction of each combination tested was characterized by calculated the fractional 
inhibitory concentrations (FICs) of each drug tested. The sum of the FICs, the so-called FIX 
index, was calculated on the basis of the MIC endpoint (MIC90 and MIC50). As a standard 
recommended by the American Society for Microbiology, synergistic, indifferent, and 
antagonistic interactions were determined to be FIX values  of  ≤  0.5,  0.5  - 4.0 and > 4.0, 
respectively. Each experiment was performed in duplicate.  
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Figure 9: Design of the Checkerboard Assay.  Fluconazole is added to all the wells in Column 1 
and its concentration halved across the plate as depicted by the arrow. No Fluconazole is added 
to Column 12. Geraniol is added to all the wells in Row A and its concentration is halved down 
the plate as depicted by the arrow. No Geraniol is added to Row H. One Candida strain is then 
added to all the wells of the plate. This setup renders well 12H as the positive control because it 
does not contain drug. The MICs of both drugs are therefore calculated based off of this control. 
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RESULTS 
 
 
Quantification of Antifungal Activity of Azoles and Polyenes 
 
The intial stage of this project characterized two known anti-fungal compounds against 
the seven acquired Candida strains.  The antifungal activity of fluconazole, an azole, and 
Amphotericin B, a polyene, were investigated using MIC assays. Fluconazole and amphotericin 
B are known to have fungistatic activity on Candida strains, and this activity was quantified 
for the seven Candida isolates. The independent anti-Candida activity of each drug was 
analyzed and reported as Minimal Inhibitory Concentration (MIC) values (Table I). Two fold 
dilutions of Fluconazole and Amphotericin B were performed serially in the MIC assays with a 
reproducibility of ±1 well between the replicates. A mean of the MIC of the strains from two 
experiments is shown in the table.  The data show that strains 4568 and 51611 are the least 
resistant to Fluconazole, while strains 51611, 14, 4568, and 10261 are the least resistant to 
Amphotericin B. 
 
Table 1: MICs of Antifungal Agents Against Candida Strains. 
 
 
 
 
MICs were determined by a micro-dilution method. The MIC was defined as the lowest 
concentration of the antifungal drug that inhibited the proliferation of Candida after a 24	  
hr	  incubation	  in	  37	̊  C.	  Experiments	  were	  run	  in	  duplicate.	  — not determined. 
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The growth inhibition curves (Figure 10) show the susceptibility of the Candida isolates 
to varying Fluconazole concentrations. It is clear that the percentage of C. albicans growth 
decreased with increasing Fluconazole concentration. To compare the extent of inhibition, one 
can either analyze the slope of each individual curve (the steeper the slope, the greater the 
percent inhibition) or one can determine the MIC50 for each strain. The figure shows that strains 
51611, 4568, 17, and 14 have the lowest MIC50 values against Fluconazole. Strains 1 and 3 have 
the greatest MIC50s. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: A line plot of C. albicans strains’ % growth with increasing 
Fluconazole concentration 
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Quantification of Antifungal Activity of Plant Essential Oils: Terpenes 
 
The antifungal activity of the terpenes, Geraniol and Carvacrol, were investigated and 
quantified using MIC assays. As with the antifungals, two-fold dilutions of Geraniol and 
Carvacrol were performed serially in the MIC assays with a reproducibility of ±1 well between 
the replicates. A mean of the independent anti-Candidal activity of each terpene from two 
experiments was analyzed and reported as Minimal Inhibitory Concentration (MIC) values in 
Table 2.  Both Geraniol and Carvacrol inhibited growth of the Candida strains. Geraniol 
showed MICs for all seven strains ranging from 0.5—2 mg/ml, while Carvacrol showed MICs 
for the five strains tested ranging from <0.125—1 mg/ml. These MIC values represent the 
minimum concentration of drug required to inhibit growth of the microbes, and the data 
suggests that Carvacrol is more potent against the resistant Candida isolates than Geraniol. 
 
Table 2: MICs of terpenes against Candida Strains 
 
 
 
 
 
MICs were determined by a micro-dilution method. The MIC was defined as the 
lowest concentration of the antifungal agent that noticeably inhibited the 
proliferation of Candida after	  24	  h	  incubation	  in	  37	̊  C.	  Experiments	  were	  run	  in	  
duplicate. —, not determined  
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The growth inhibition curves in Figure 11 show the susceptibility of the Candida 
isolates to varying Geraniol concentration. It is clear from the combined line plot that the 
percentage of C. albicans growth decreased with increasing Geraniol concentration. The extent 
of inhibition was measured by the slope of each individual curve and takes into account the 
degree by which the starting population of the strain was reduced. The data suggests that Strain 
17 is slightly more sensitive followed by 4568 as these strains have the largest gradients. Strain 
51611 (light blue curve), the control for Fluconazole, is notably the most resistant to Geraniol 
as it shows the greatest MIC50 value. The graph of Figure 11 allows a comparison of the 
sensitivity of the different strains to varying Geraniol concentrations along a wider range of 
concentrations, and correlates with the MIC data reported in Table 2. 
 
 
 
 
 
 
 
  
Figure 11: Plot of % C. albicans strains’ % growth with increasing Geraniol 
concentrations. 
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Synergistic Effect of Drugs In Combination Against Resistant C. albicans  
 
Once the susceptibilities of the resistant strains to Fluconazole and Geraniol were 
established, investigations into the potential synergistic effect of Geraniol on Fluconazole were 
conducted.  Synergy was investigated using a Checkerboard micro-dilution assay referenced in 
the Methods and Materials. This assay facilitated the study of the effect of different 
concentrations of Geraniol and Fluconazole together on Candida growth. Microscopic and 
spectrophotometric analysis of the plates showed that the extent of turbidity in the wells of the 
96 well plates positively correlated with the degree of effectiveness of the combined antifungal 
agent and terpene.  
Figures 12-16 below show the effect of combining Fluconazole and Geraniol on growth 
of each of the five tested Candida strains. The spectrophotometric reading is reported for 
Fluconazole concentrations ranging from 0.002-2.50 mg/ml after a twenty-four hour incubation 
period at a sub-inhibitory Geraniol concentration of 0.125 mg/ml. The plots clearly show that 
the turbidity of the wells treated with a combination of both compounds is low, and the 
combination of drugs had lower spectrophotometric readings than the wells that were only 
treated with Fluconazole. The turbidity of the well correlates proportionally with yeast growth.   
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Figures 12-16: Synergistic effect of combining Flucanazole with Geraniol on 
spectrophotometric readings, for all five tested strains. 
 
A summary of the synergy assays based on MIC50 values are given in Table 3 below. 
The data is a mean of two experiments per strain. The Fractional Inhibitory Concentration (FIC) 
value was the quotient of the MIC of the drugs in combination, and the MIC of the drug 
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individually. The Fractional Inhibitory Concentration Index (FIX) was the sum of the FIC values 
of Geraniol and Fluconazole for a given Candida strain. Synergy was determined using the 
guidelines set by the Department of Microbiology. FIX values less than or equal to 0.5 were 
determined to represent synergies induced by the drug combination, FIX values between 0.5 and 
4 were determined to represent indifference, and FIX values above 4.0 were determined to 
represent antagonism in the drug combinations. The results show that based on MIC50 values, 
synergy was achieved for all five strains tested. The MIC values for all the fluconazole + 
geraniol combinations were much lower than the MIC values for the drugs individually. 
 
 
Table 3: Synergy of Fluconazole and Geraniol Against 
Candida Strains Based on MIC50. 
 
Candida 
Strain 
MIC50 (ug/ml) of: 
FIX Result Fluc with 
Geraniol Fluc 
1 <4.88 >5000 0.001 Synergy 
14 56 625 0.090 Synergy 
17 156 625 0.250 Synergy 
4568 156 625 0.250 Synergy 
51611 2.44 39 0.062 Synergy 
 
 
 Fractional Inhibitory Concentration Index (FIX) is equal to (MIC of 
drug in combination/MIC of drug alone)  
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DISCUSSION 
 
 
Quantification of Antifungal Activity of Azoles and Polyenes 
 
Azoles and Polyenes are known to inhibit Candida growth via interactions with the 
ergosterol metabolic pathway, and by forming stacking barrels with ergosterol containing 
membranes, respectively. The results reported in Table 1 highlight the employment of different 
resistance mechanisms by the C. albicans strains used in this study.  The major C. albicans drug 
resistance mechanisms reported in previous studies are: mutation in the ERG11 gene, 
overexpression of the mutated gene, and overexpression of the efflux pump. Mutation and/or 
overexpression of the ERG11 gene alter the structure of Lanosterol  14α-demethylase, the 
substrate to which azoles bind, thereby rendering the azole ineffective. Overexpression of the 
efflux pump causes the drug to be ejected out of the cytosol, resulting in a similar consequence 
as with the previous two mechanisms.  
All six resistant Candida strains tested in this project showed growth inhibition with 
increased Fluconazole concentrations in Figure 10.  Strain 4568 was observed to be the most 
sensitive to Fluconazole, yet the most resistant to Amphotericin B. This suggests that Strain 4568 
is susceptible to azole blocking of ergosterol synthesis, yet that it is able to overcome the 
polyene’s  disruption  of  the  cells’  ergosterol  membrane.  This  resistance  mechanism  might  be  
manifested via a loss of function mutation in the ERG3 gene which leads to blocking the 
production of ergosterol and the formation of a drug-lipid complex (Kelly et al., 1997). 
Strains 4568, 17, and 14 showed intermediate resistance to Fluconazole, and likely 
employ a different pathway of resistance other than ERG11 mutation or overexpression. Strains 
1, 3 and 102611 are clearly the most resistant to Fluconazole, and likely employ different 
resistance mechanisms.  
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Quantification of Antifungal Activity of Plant Essential Oils: Terpenes 
 
Plant essential oils are documented to have antimicrobial action. Research suggests that 
terpenes destroy and damage the cellular membrane, moving into the cell membrane by diffusion 
(Andrews et al., 1980). The results reported in Table 2 show the antifungal activity of both 
Geraniol and Carvacrol, pointing to the latter to be more effective at inhibiting the growth of the 
tested isolates. Even though the strains are resistant to Fluconazole, the terpenes were able to 
uniformly inhibit their growth at low concentrations of over a range of 0.5—2 mg/ml for 
Geraniol, and <0.125—1 mg/ml, when Carvacrol was used. This shows that the azole resistance 
mechanisms in these isolates were ineffective at overcoming the antifungal activities of these 
terpenes. 
A trend of growth inhibition across the five Candida strains with increased Geraniol 
concentrations was seen in Figure 11. This demonstrates the activity of Geraniol alone on C. 
albicans. 
 
Interactions Between Fluconazole and Geraniol 
 
The data in Figures 12-16 clearly show greater inhibition of Candida growth by the 
Fluconazole-Geraniol drug combination when compared with just Fluconazole alone. The 
figures demonstrate that ineffective levels of fluconazole alone become active in combination 
with sub-MIC levels of Geraniol (0.125 mg/ml), substantially inhibiting resistant C. albicans 
growth. The Fluconazole only curve across the five strains shows a high initial OD reading due 
to higher growth levels at ineffective Fluconazole levels. These OD readings decrease with 
increasing Fluconazole concentrations to equal to and above MIC levels. The Fluconazole-
Geraniol data-set for every strain shows a much lower initial OD for sub-MIC Fluconazole and 
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sub-MIC Geraniol concentration in combination. In summary, the sub-MIC drug combination 
yielded greater killing of the four resistant strains as well as the sensitive strain.  
The synergy results reported in Table 3 report FIX values of below 0.5 for all five tested 
strains, which demonstrates that the investigations were successful in proving that Geraniol has 
the potential to enhance the antifungal activity of Fluconazole against drug-resistant C. albicans. 
 
Reliability of Results 
 
Due to inevitable pipetting variations between operators, the MIC determined for the 
Candida isolates varied with an error of about  +/- one well on the 96-well plate.  Also, the 
average of two experiments was taken for each MIC value reported in Tables 2-3 as well as 
Figures 10-16.  Looking at the bigger picture, this variability does not cause a significant 
difference in fungistatic activity of the terpene, or in the FIX value calculated. As such, the MIC 
data and synergy results reported allow us to conclude Geraniol has the potential to enhance the 
antifungal activity of Fluconazole against drug-resistant C. albicans. 
 
Future Implications 
 
Further studies should be conducted using different antifungal drugs and terpenes. The 
enhancing potential of Geraniol on other azoles like Ketoconazole, as well as polyenes like 
Amphotericin B should be investigated. A deterring factor in the clinical use of Amphotericin B 
is the fact that it is toxic in high concentrations. The potential for Geraniol to reduce the MIC 
value of Amphotericin B should therefore be explored with the goal of rendering Amphotericin 
B potent at sub-toxic levels.  
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The results reported in this study show that Carvacrol is a more potent terpene than 
Geraniol. Further studies should therefore be conducted into the effect of Carvacrol on other 
anti-fungal drugs with the hope that it can reduce the MIC values to lesser ones than those 
reported for Fluconazole-Geraniol combinations. 
Investigations should also be performed to conduct efficient loading of the antifungal-
terpene drug combinations into micro-particles or liposomes. These studies would facilitate more 
effective drug delivery to targeted tissues, such as macrophages. In addition, the next step of this 
study should involve testing the drug-combinations in vivo, in mice. A crucial part of this step 
will involve monitoring the drug toxicity levels in vivo, as well as determining that targeted 
delivery is achieved. This can be done by attaching a fluorescent compound, such as fluorescein 
to the drug and monitoring the organs of the mouse to which delivery is achieved. The time 
required achieving delivery using different delivery vehicles such as glucan microparticles and 
liposomes could also be scored to determine the most effective delivery mechanism. 
The grander impact of these results involves the use of antifungal-terpene drug 
combinations to yield greater potency against fungal infections. The increased potency of the 
drug combinations could result in the elimination of the problem of the reoccurrence of Candida 
infections due to resistant strains, and could save resources currently used by hospitals and 
patients to battle resistant Candida infections. 
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CONCLUSIONS 
 
 
Our results demonstrate synergy between Fluconazole, an antifungal drug, and Geraniol, 
a monoterpenoid component of an essential plant oil. The fact that essential plant oils lack 
harmful compounds makes Geraniol a good enhancer for antifungal activity. This demonstrated 
relationship should be investigated for additional antifungals and essential plant oils. The drug 
combinations should be loaded in suitable drug delivery vehicles to facilitate targeted delivery to 
tissues and their effect tested in vivo in order to monitor toxic effects and tissue specificity. On a 
grander scale, the demonstrated synergy offers the potential of significantly reducing the issues 
with recurrent Candida infections due to resistant strains. 
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